Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Allogene Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALLO
Nasdaq
8731
https://allogene.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Allogene Therapeutics Inc
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
- Apr 24th, 2024 2:01 pm
3 Meme Stocks to Sell and Replace With Meme Coins
- Apr 11th, 2024 6:45 pm
Allogene Therapeutics Announces Q2 Investor Conference Participation
- Apr 9th, 2024 12:30 pm
How Allogene (ALLO) Stock Stands Out in a Strong Industry
- Apr 8th, 2024 12:46 pm
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
- Apr 7th, 2024 2:22 pm
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
- Mar 16th, 2024 8:35 pm
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
- Mar 15th, 2024 1:32 pm
Q4 2023 Allogene Therapeutics Inc Earnings Call
- Mar 15th, 2024 11:04 am
Allogene Therapeutics Inc (ALLO) Reports Q4 and Full Year 2023 Financials, Forecasts Cash ...
- Mar 14th, 2024 9:34 pm
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
- Mar 14th, 2024 9:15 pm
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Mar 14th, 2024 8:05 pm
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
- Mar 13th, 2024 4:15 pm
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
- Mar 12th, 2024 12:50 pm
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
- Mar 12th, 2024 12:30 pm
Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross
- Mar 5th, 2024 2:55 pm
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
- Mar 5th, 2024 1:30 pm
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
- Feb 28th, 2024 1:30 pm
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
- Feb 16th, 2024 1:30 pm
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
- Jan 16th, 2024 9:05 pm
Allogene (ALLO) Down 20% on Strategic Changes in Pipeline
- Jan 5th, 2024 5:52 pm
Scroll